Alpine Immune Sciences Inc (ALPN)
64.97
0.00 (0.00%)
USD |
NASDAQ |
May 20, 16:00
Alpine Immune Sciences Cash from Financing (TTM): 185.56M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 185.56M |
December 31, 2023 | 165.12M |
September 30, 2023 | 20.06M |
June 30, 2023 | 111.67M |
March 31, 2023 | 102.25M |
December 31, 2022 | 102.69M |
September 30, 2022 | 102.02M |
June 30, 2022 | 98.88M |
March 31, 2022 | 99.91M |
December 31, 2021 | 100.76M |
September 30, 2021 | 89.88M |
June 30, 2021 | 56.59M |
March 31, 2021 | 56.58M |
December 31, 2020 | 61.38M |
September 30, 2020 | 61.39M |
June 30, 2020 | 6.648M |
March 31, 2020 | 6.137M |
December 31, 2019 | 24.26M |
September 30, 2019 | 23.76M |
Date | Value |
---|---|
June 30, 2019 | 21.61M |
March 31, 2019 | 22.12M |
December 31, 2018 | -0.991M |
September 30, 2018 | -0.491M |
June 30, 2018 | 42.70M |
March 31, 2018 | |
December 31, 2017 | |
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | 41.17M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
6.137M
Minimum
Mar 2020
185.56M
Maximum
Mar 2024
74.86M
Average
75.64M
Median
Cash from Financing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -625.00M |
Eliem Therapeutics Inc | 0.855M |
Regeneron Pharmaceuticals Inc | -1.420B |
Vera Therapeutics Inc | 302.10M |
Eyenovia Inc | 19.53M |